Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

**Medications for Dental Procedures Approval** 

I, Christine Maree Connors, Chief Health Officer:

(a) under section 254(1) of the Act, approve each Scheduled substance treatment protocol

specified in Schedule A;

(b) under section 254(3) of the Act, state that each Schedule substance treatment protocol

specified in Schedule A remains in effect for a period of 2 years on and from the date

of this instrument.

Dated 28 March 2025

EDOC2025/79943

Chief Health Officer

## Schedule A

Title	Publication Date	Author	
Medications for Dental	25 March 2025	Commissioning and System	
Procedures SSTP		Improvement, Northern	
		Territory Government,	
		Department of Health	

## Medications for Dental Procedures SSTP

	I			
Areas Applicable	NT Wide			
Health Professionals authorised by this SSTP	Dental Therapists or Oral Health Therapists employed by or contracted to NT Health			
Scheduled Substance(s)	Articaine Lidocaine Mepivacaine Prilocaine Clindamycin when prepared in combination with Triamcinolone for treatment of dental pulp Triamcinolone when used in dental preparations for the treatment of dental pulp Felypressin when used in combination with a local anaesthetic for local anaesthetic of the mouth as part of dental procedures Tranexamic acid where prepared in a topic solution for treatment of minor			
	bleeding associated with dental procedures			
Indication	Peri-operative and post-operative management of interventional oral and dental procedures.			
Contraindications and/or Exclusions*	As per Australian Therapeutic Guidelines: Oral and Dental (current version)			
Dose and Route <sup>*</sup>	As per Australian Therapeutic Guidelines: Oral and Dental (current version)			
Dose Frequency*	As per Australian Therapeutic Guidelines: Oral and Dental (current version)			
Drug Interactions*	As per manufacturers' product information advice			
Monitoring requirements*	As per Australian Therapeutic Guidelines: Oral and Dental (current version)			
Health Professional Accreditation Requirements	<ul> <li>Health professionals using this guideline must meet the requirements outlined by the NT Chief Health Officer:</li> <li>All health professionals following this protocol must:</li> <li>Be registered with the Dental Board of Australia in the appropriate division of registration, with no conditions, undertakings or notations that limit delivery of clinical services.</li> </ul>			
	<ul> <li>Have completed medicines training in accordance with the approved Oral Health Scheduled Substance Treatment Protocol (SSTP) Training Manual, including all end-of-module assessments, at least once in the previous 24 months.</li> </ul>			



	<ul> <li>Maintain continuing professional development related to skills and competencies required for the delivery of medicines</li> </ul>			
	Hold a current Basic Life Support Certificate or Provide First Aid Certificate, and provide documentary evidence of the qualifications when required			
Documentation (including necessary information to the patient)	Reason for administration, dose and time given to be entered into the individual patient record in the Patient Information System.			
Related Documents	Therapeutic Guidelines (Oral and Dental) – current version,  MIMS Annual – current version,  Medicines and Poisons Regulations 2014 – Section 73 – Retention of documents relating to receipt or supply of Scheduled substances			
	Medicines and Poisons Regulations 2014 – Section 75 – Record of supply or administration of Schedule 4 or 8 substance in clinical or other records.			
Chief Health Officer	Signature	Name	Date	
	EDOC2025/79941	Adj Prof Christine Connors	28/03/2025	
Period of effect	This SSTP remains in force until 28/03/2027 unless revoked earlier			

## References:

<sup>\*</sup> The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration